Phathom Pharmaceuticals (PHAT) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $6.92, -7.73% vs the prior close of $7.50.
- Volume 1.25M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PHAT slides 7.7% to $6.92. Closed at $6.92, -7.73% vs the prior close of $7.50. Day range $6.90–$7.57, opened at $7.51.
PHAT daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — PHAT slides 7.7% to $6.92
- Closed at $6.92, -7.73% vs the prior close of $7.50. Day range $6.90–$7.57, opened at $7.51.
- Volume was 1.25M shares, 1.0x its 50-day average of 1.30M.
- Price is -15.2% vs its 50-day average ($8.16) and -36.6% vs its 200-day average ($10.91).
- 52-week range $6.52–$18.31; today's close sits at 3% of that range, 62.2% below the 52-week high.
Oct 15, 2026 — PHAT rises 1.4% to $7.50
- Closed at $7.50, +1.35% vs the prior close of $7.40. Day range $7.41–$7.69, opened at $7.54.
- Volume was 1.21M shares, 0.9x its 50-day average of 1.31M.
- Price is -8.4% vs its 50-day average ($8.19) and -31.6% vs its 200-day average ($10.96).
- 52-week range $6.52–$18.31; today's close sits at 8% of that range, 59.0% below the 52-week high.
Oct 14, 2026 — PHAT jumps 5.7% to $7.40
- Closed at $7.40, +5.71% vs the prior close of $7.00. Day range $6.92–$7.72, opened at $6.97.
- Volume was 1.72M shares, 1.3x its 50-day average of 1.32M.
- Price is -9.8% vs its 50-day average ($8.20) and -32.8% vs its 200-day average ($11.01).
- 52-week range $6.52–$18.31; today's close sits at 7% of that range, 59.6% below the 52-week high.
Oct 13, 2026 — PHAT dips 1.8% to $7.00
- Closed at $7.00, -1.82% vs the prior close of $7.13. Day range $6.86–$7.16, opened at $7.14.
- Volume was 1.95M shares, 1.5x its 50-day average of 1.31M.
- Price is -14.9% vs its 50-day average ($8.22) and -36.7% vs its 200-day average ($11.06).
- 52-week range $6.52–$18.31; today's close sits at 4% of that range, 61.8% below the 52-week high.
Oct 12, 2026 — PHAT dips 1.7% to $7.13
- Closed at $7.13, -1.66% vs the prior close of $7.25. Day range $7.03–$7.28, opened at $7.25.
- Volume was 1.01M shares, 0.7x its 50-day average of 1.36M.
- Price is -13.7% vs its 50-day average ($8.26) and -35.9% vs its 200-day average ($11.11).
- 52-week range $6.52–$18.31; today's close sits at 5% of that range, 61.1% below the 52-week high.
Oct 9, 2026 — PHAT rises 1.7% to $7.25, 4 up days in a row
- Closed at $7.25, +1.68% vs the prior close of $7.13. Day range $7.01–$7.30, opened at $7.13.
- Volume was 928.30K shares, 0.6x its 50-day average of 1.49M.
- Price is -12.6% vs its 50-day average ($8.29) and -35.1% vs its 200-day average ($11.17).
- 52-week range $6.52–$18.31; today's close sits at 6% of that range, 60.4% below the 52-week high.
- That makes 4 straight gains.
Oct 8, 2026 — PHAT jumps 4.7% to $7.13, 3 up days in a row
- Closed at $7.13, +4.70% vs the prior close of $6.81. Day range $6.68–$7.18, opened at $6.79.
- Volume was 1.33M shares, 0.9x its 50-day average of 1.48M.
- Price is -14.4% vs its 50-day average ($8.33) and -36.4% vs its 200-day average ($11.22).
- 52-week range $6.52–$18.31; today's close sits at 5% of that range, 61.1% below the 52-week high.
- That makes 3 straight gains.
Oct 7, 2026 — PHAT rises 0.4% to $6.81
- Closed at $6.81, +0.44% vs the prior close of $6.78. Day range $6.60–$7.03, opened at $6.87.
- Volume was 1.63M shares, 1.1x its 50-day average of 1.46M.
- Price is -19.1% vs its 50-day average ($8.42) and -39.6% vs its 200-day average ($11.27).
- 52-week range $6.52–$18.31; today's close sits at 2% of that range, 62.8% below the 52-week high.
Oct 6, 2026 — PHAT rises 1.2% to $6.78
- Closed at $6.78, +1.19% vs the prior close of $6.70. Day range $6.52–$6.80, opened at $6.75.
- Volume was 2.09M shares, 1.5x its 50-day average of 1.44M.
- Price is -20.4% vs its 50-day average ($8.52) and -40.1% vs its 200-day average ($11.32).
- 52-week range $6.52–$18.31; today's close sits at 2% of that range, 63.0% below the 52-week high.
Oct 5, 2026 — PHAT slides 3.2% to $6.70, a 52-week low, 4 down days in a row
- Closed at $6.70, -3.18% vs the prior close of $6.92. Day range $6.64–$7.00, opened at $6.95.
- Volume was 1.10M shares, 0.8x its 50-day average of 1.43M.
- Price is -22.3% vs its 50-day average ($8.62) and -41.0% vs its 200-day average ($11.36).
- 52-week range $6.64–$18.31; today's close sits at 0% of that range, 63.4% below the 52-week high.
- That makes 4 straight losses.
Oct 2, 2026 — PHAT dips 2.3% to $6.92, a 52-week low, 3 down days in a row
- Closed at $6.92, -2.26% vs the prior close of $7.08. Day range $6.82–$7.23, opened at $7.20.
- Volume was 1.68M shares, 1.2x its 50-day average of 1.41M.
- Price is -20.6% vs its 50-day average ($8.71) and -39.3% vs its 200-day average ($11.40).
- 52-week range $6.82–$18.31; today's close sits at 1% of that range, 62.2% below the 52-week high.
- That makes 3 straight losses.
PHAT latest news & SEC filings
Every SEC filing by or about PHAT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Narula Sanjeev had withheld for taxes 13,485 shares at $6.78 (≈$91.43K) on Oct 6, 2026; now holds 214,718
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 30, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $74.27M (prior year $39.50M) (+88.0% vs Jun 30, 2025)
- Net income: -$17.58M (prior year -$75.81M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.21 (prior year -$1.05) (loss narrowed vs Jun 30, 2025)
Jul 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 29, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 20, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade PHAT
- Last results release: Jul 30, 2026 (8-K Item 2.02). Previous ones: Apr 30, 2026, Feb 26, 2026, Jan 7, 2026. Based on that rhythm, the next report is likely around Oct 29, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.77% (largest 10.0%).
- Liquidity: about 1.34M shares (≈$9.31M) trade per day on average.
- 52-week position: $6.92 vs a range of $6.52–$18.31 (3% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 4 sales; latest: Robert Charles Breedlove sold 524 shares on Nov 3, 2025.
- Latest filings: 8-K Sep 29, 2026; 10-Q Jul 30, 2026; 8-K Jul 30, 2026.
- Share count: 80.90M shares outstanding (Jul 27, 2026), +14.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
PHAT market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 7.51 | 7.57 | 6.90 | 6.92 | 1.25M |
| Oct 15, 2026 | 7.54 | 7.69 | 7.41 | 7.50 | 1.21M |
| Oct 14, 2026 | 6.97 | 7.72 | 6.92 | 7.40 | 1.72M |
| Oct 13, 2026 | 7.14 | 7.16 | 6.86 | 7.00 | 1.95M |
| Oct 12, 2026 | 7.25 | 7.28 | 7.03 | 7.13 | 1.01M |
| Oct 9, 2026 | 7.13 | 7.30 | 7.01 | 7.25 | 928.30K |
| Oct 8, 2026 | 6.79 | 7.18 | 6.68 | 7.13 | 1.33M |
| Oct 7, 2026 | 6.87 | 7.03 | 6.60 | 6.81 | 1.63M |
| Oct 6, 2026 | 6.75 | 6.80 | 6.52 | 6.78 | 2.09M |
| Oct 5, 2026 | 6.95 | 7.00 | 6.64 | 6.70 | 1.10M |
| Oct 2, 2026 | 7.20 | 7.23 | 6.82 | 6.92 | 1.68M |
| Oct 1, 2026 | 7.47 | 7.47 | 7.08 | 7.08 | 1.06M |
| Sep 30, 2026 | 7.40 | 7.50 | 7.19 | 7.30 | 809.10K |
| Sep 29, 2026 | 7.34 | 7.45 | 7.18 | 7.36 | 657.20K |
| Sep 28, 2026 | 7.30 | 7.41 | 7.15 | 7.35 | 1.69M |
| Sep 25, 2026 | 7.10 | 7.38 | 7.09 | 7.30 | 1.44M |
| Sep 24, 2026 | 6.98 | 7.19 | 6.91 | 7.08 | 1.42M |
| Sep 23, 2026 | 7.82 | 7.82 | 6.98 | 6.99 | 1.04M |
| Sep 22, 2026 | 7.58 | 7.84 | 7.40 | 7.76 | 1.95M |
| Sep 21, 2026 | 7.54 | 7.62 | 7.31 | 7.45 | 898.90K |
About Phathom Pharmaceuticals
Phathom Pharmaceuticals (PHAT) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in FLORHAM PARK, NJ. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1783183.
PHAT board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Steven L Basta | President and CEO | Feb 12, 2026 |
| Michael F Cola | Director | May 21, 2026 |
| Heidi Fields | Director | May 21, 2026 |
| Frank Karbe | Director | May 21, 2026 |
| Asit Parikh | Director | May 27, 2026 |
| Theodore R Schroeder | Director | May 21, 2026 |
| Mark Stenhouse | Director | May 21, 2026 |
| James N Topper | Director | May 21, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Steven L Basta | President and CEO | Feb 12, 2026 |
| Robert Charles Breedlove | Principal Accounting Officer | Sep 8, 2026 |
| Anne Marie Cook | Chief Legal Off. & Corp. Sec. | Feb 12, 2026 |
| Sanjeev Narula | Chief Financial & Bus. Officer | Jan 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Nov 3, 2025 | Robert Charles Breedlove | Sale | 524 | $13.51 |
| Nov 3, 2025 | Robert Charles Breedlove | Sale | 524 | $13.51 |
| Nov 3, 2025 | Robert Charles Breedlove | Sale | 524 | $13.51 |
| Nov 3, 2025 | Robert Charles Breedlove | Sale | 524 | $13.51 |
PHAT financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $175.11M | $-221.25M | -3.03 | $-166.78M |
| Dec 31, 2024 | $55.25M | $-334.33M | -5.29 | $-266.77M |
| Dec 31, 2023 | $682.00K | $-201.59M | -3.93 | $-137.58M |
| Dec 31, 2022 | $0 | $-197.72M | -5.05 | $-146.53M |
| Dec 31, 2021 | — | $-143.88M | -3.89 | $-148.46M |
Latest balance sheet: total assets $327.07M, total liabilities $671.35M, cash $182.48M (as of Jun 30, 2026).
PHAT earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 30, 2026 | 8-K Item 2.02 (results) | $9.03 |
| Apr 30, 2026 | 8-K Item 2.02 (results) | $11.20 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $13.56 |
| Jan 7, 2026 | 8-K Item 2.02 (results) | $18.08 |
| Oct 30, 2025 | 8-K Item 2.02 (results) | $13.31 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $9.40 |
| May 1, 2025 | 8-K Item 2.02 (results) | $3.36 |
| Mar 6, 2025 | 8-K Item 2.02 (results) | $5.90 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $18.50 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 7, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on PHAT
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.